Cancer Targeted Technology Receives Fast Track $2.4M Grant to Develop an Innovative PSMA-Targeted Small Molecule Drug Conjugate for Prostate Cancer November 26, 2024
First patient dosed in Ph 3 trial HLX22-GC-301 of HLX22 in combination with trastuzumab and chemo in 1L HER2+ve advanced G/GEJ cancer patients November 26, 2024
ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial Completed and CRR of 71% with a Durable DoR Ranging Up to 54 Months reported November 26, 2024
Results from End-of-Phase 2 Meeting with FDA for IMNN-001 Program in Advanced Ovarian Cancer Announced November 26, 2024
Incyclix Bio and Lilly to test INX-315 + Verzenio and Fulvestrant in HR+/HER2- Breast Cancer November 26, 2024
First Patient Dosed in Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies November 26, 2024
Ph 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints November 26, 2024
FDA Accepts Supplemental NDA for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic HSPC November 26, 2024
Ratio Therapeutics Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate November 26, 2024
Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline November 26, 2024
VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific ADC November 26, 2024
Vyriad announces strategic collaboration with Novartis to develop in vivo CAR-T cell therapies November 26, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias November 26, 2024
Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer November 26, 2024
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology November 26, 2024
Enrollment of 68 patients completed in Ph 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule November 26, 2024
TUSCANY Ph 1/2 Study for Newly Diagnosed AML Patients Initiated to Receive Tuspetinib-based Triplet Therapy November 26, 2024
First Patient Enrolled in Ph 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors November 26, 2024
First Patient dosed in Ph 1/2 Clinical Study of GPR65 Inhibitor PTT-4256 in Patients with Advanced Solid Cancers November 26, 2024
SRN-101 announced as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA November 26, 2024
ALISCA-Breast1 Ph 2 Trial of Alisertib initiated in HR+ve, HER2-Negative Metastatic Breast Cancer November 26, 2024
